Company: INSP
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001609550-25-000053
Chunk: 68

Company: Inspire Medical Systems, Inc.
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 8
Chunk 68
---
 original maturities of 90 days or less from the date of purchase to be cash equivalents. Cash is carried at cost, which approximates fair value, and cash equivalents, which consist of money market funds, are stated at fair value.Foreign CurrencyOur functional and reporting currency is the U.S. dollar. Our subsidiaries have functional currency in Euro and Yen. The consolidated financial statements are translated to U.S. dollars. Non-monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated using the balance sheet date exchange rate. Sales and expenses denominated in foreign currencies are translated at transaction date exchange rates. Foreign currency transaction gains and losses and the impacts of foreign currency remeasurement are recognized in other expense (income), net in the consolidated statements of operations and comprehensive income. For the three-month periods ended September 30, 2025 and 2024, we recognized $0.1 million of loss and $0.1 

10

Table of ContentsInspire Medical Systems, Inc. Notes to Consolidated Financial Statements (unaudited) (Table amounts in thousands, except share and per share amounts)

million of gain, net, respectively. For the nine-month periods ended September 30, 2025 and 2024 we recognized $1.0 million of gain and $0.1 million of loss, net, respectively. Any unrealized gains and losses due to translation adjustments are included in accumulated other comprehensive income within stockholders' equity in the consolidated balance sheets. We had $0.0 million and $0.2 million of unrecognized gain in our accumulated other comprehensive income balance as of September 30, 2025 and December 31, 2024, respectively.InvestmentsOur investments are classified as available-for-sale and consisted of the following:September 30, 2025AmortizedUnrealized GrossAggregateCostGainsLossesFair ValueShort-Term:Commercial paper$21,903 $24 $— $21,927 Corporate debt securities45,854 145 — 45,999 U.S. treasury debt securities141,612 213 (4)141,821 Short-term investments$209,369 $382 $(4)$209,747 Long-Term:Corporate debt securities$51,977 $139 $(10)$52,106 U.S. treasury debt securities36,